VX-765: Selective Oral Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a potent, selective, orally absorbed pro-drug that inhibits caspase-1 activity, thereby blocking the maturation and release of IL-1β and IL-18, key inflammatory cytokines (Exconde et al., 2023). The compound is metabolized in vivo to VRT-043198, its active form, which demonstrates minimal off-target effects on other cytokines. VX-765 serves as a critical tool for studying pyroptosis in macrophages and has shown efficacy in preclinical models of arthritis, skin inflammation, and HIV-associated CD4 T-cell death. The product is available from APExBIO as SKU A8238 and is widely used in research workflows due to its robust selectivity and pharmacokinetics (APExBIO product page).

Biological Rationale

Inflammasomes are multiprotein complexes that detect pathogenic or damage signals in the cytosol. Canonical inflammasomes recruit and activate caspase-1, also known as interleukin-1 converting enzyme (ICE), which cleaves pro-IL-1β and pro-IL-18 into their mature, biologically active forms (Exconde et al., 2023). Caspase-1 also processes gasdermin D, initiating pyroptosis, a lytic form of programmed cell death prevalent in macrophages. This pathway is central to innate immune responses and is implicated in the pathogenesis of numerous inflammatory and autoimmune diseases. Targeting caspase-1 selectively enables the dissection of its role apart from other inflammatory mediators such as IL-6, IL-8, or TNFα. VX-765, by specifically inhibiting caspase-1, allows researchers to interrogate these pathways and distinguish canonical from non-canonical inflammasome activation (Precision Targeting of Caspase-1 with VX-765). This article extends on that by providing granular, evidence-grounded benchmarks.

Mechanism of Action of VX-765

VX-765 is an orally bioavailable pro-drug that is converted in vivo to VRT-043198, the active metabolite (APExBIO). VRT-043198 binds selectively to the active site of caspase-1, blocking the cleavage of pro-IL-1β and pro-IL-18. This inhibition is highly specific, with negligible activity against other caspases (e.g., caspase-3, -4, -5, -11) or cytokine pathways. The inhibition prevents caspase-1-mediated processing of gasdermin D, thereby suppressing the pore formation required for pyroptosis (Exconde et al., 2023). This mechanism enables VX-765 to reduce inflammatory cytokine release and block pyroptotic cell death in response to intracellular pathogens or sterile inflammation.

Evidence & Benchmarks

• VX-765 reduces IL-1β and IL-18 secretion in human and murine immune cells exposed to canonical inflammasome activators, with no significant effect on IL-6, IL-8, or TNFα production (bioRxiv, Fig. 3).
• In vivo, VX-765 administration (oral, 25–100 mg/kg) significantly decreases joint swelling and cytokine levels in collagen-induced arthritis mouse models (APExBIO).
• VX-765 prevents CD4 T-cell pyroptotic death in human lymphoid tissues infected with HIV in a dose-dependent manner (Precision Targeting of Caspase-1 with VX-765).
• Enzyme inhibition assays show VX-765 (IC₅₀ in low nanomolar range, pH 7.5 buffer) potently blocks caspase-1 activity without cross-inhibiting caspase-3 in biochemical assays (VX-765: Selective Caspase-1 Inhibitor).
• Oral dosing in rodents demonstrates high bioavailability and rapid conversion to VRT-043198, with plasma half-life supporting once-daily dosing (APExBIO).

Applications, Limits & Misconceptions

VX-765 is primarily employed in mechanistic studies of inflammasome signaling, pyroptosis, and cytokine biology. It is used to:

• Dissect the role of caspase-1 in autoimmune and inflammatory models (e.g., arthritis, skin inflammation).
• Investigate pyroptosis in macrophages and its contribution to host defense or pathology.
• Evaluate the impact of caspase-1 inhibition on HIV-associated CD4 T-cell loss.
• Profile cytokine responses downstream of inflammasome activation in vitro and in vivo.

For further practical guidance, see VX-765 (SKU A8238): Reliable Caspase-1 Inhibition for Reproducible Workflows, which focuses on troubleshooting and reproducibility, while this article provides updated mechanistic context and latest peer-reviewed findings.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit non-canonical inflammasome caspases (e.g., caspase-4, -5, -11); thus, it will not block all forms of pyroptosis (Exconde et al., 2023).
• It does not affect the secretion of cytokines such as IL-6, IL-8, or TNFα, which are regulated independently of caspase-1.
• VX-765 is insoluble in water; improper solvent selection can lead to precipitation and assay failure (use DMSO or ethanol as specified by the manufacturer).
• Long-term storage of solutions at room temperature can result in compound degradation; recommended to store desiccated at -20°C and use solutions short-term only (APExBIO).
• Over-interpretation of effects in complex in vivo models without confirming caspase-1 selectivity may confound results.

Workflow Integration & Parameters

For experimental workflows, VX-765 (SKU A8238) from APExBIO is supplied as a solid compound. It is insoluble in water but readily dissolves in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with ultrasonication). Typical enzyme inhibition assays are conducted at pH 7.5 in buffered conditions with stabilizing additives. Recommended storage is desiccated at -20°C; working solutions should be freshly prepared for each experiment. Oral administration in animal studies is supported by high bioavailability of the compound. Researchers should titrate concentrations to their specific system, usually in the 0.1–50 µM range for in vitro applications. For integration into inflammation workflows, see VX-765 and the Caspase Signaling Frontier, which discusses strategic design, while this article provides updated selectivity and mechanistic clarifications.

Conclusion & Outlook

VX-765 remains a cornerstone tool for dissecting the caspase-1 signaling pathway and the biology of IL-1β and IL-18 maturation. Its selectivity and oral bioavailability make it suitable for both in vitro and in vivo studies. Ongoing research is expanding its applications in autoimmune disease, viral infections, and neuroinflammation. For detailed product information or to order the A8238 kit, see the APExBIO VX-765 product page. As research advances, VX-765 continues to enable new mechanistic insights and therapeutic hypotheses in inflammation and cell death biology.